bioGenous BIOTECH, Inc.—Leading Organoid CRDMO Technology Platform

bioGenous BIOTECH Inc,

Leading Organoid CRDMO Technology Platform

One-stop Supplier

bioGenous was founded in March 2021 and completed its group reorganization in September 2022, with its headquarters located in Suzhou Industrial Park. bioGenous is dedicated to providing standardized organoid products and integrated technical services, covering three key application scenarios: basic research, precision medicine, and drug R&D. The founding team has been conducting in-depth research in technological innovations in the organoid industry, having established the world's first human-derived organoid COVID-19 infection model, blastoma models, and other disease models for new drug development platforms. They have also developed the world's first organoid-scenario equipment and AI-based drug screening platform, as well as an innovative organoid model construction platform based on tissue and tumor microenvironment analysis. bioGenous offers a full range of reagents and kits for multiple lineages and cancer types, as well as comprehensive CDMO and CRO technical services throughout the whole process.

bioGenous adheres to the vision of “Landscape of human organoids; Ideal models in clinics and research". With a core team of top-tier international R&D talent, our mission is to provide a “globally leading organoid model platform”. We are committed to delivering high-quality and efficient services to enhance our clients' drug R&D efficiency and basic research capabilities, ensuring that good medicines benefit the public at an earlier time.

Our Mission

To be a global pioneer in organoid model platforms
Our Vision

Landscape of human organoids, Ideal model in clinics and research
Our Value

Resilience Integrity Focus Responsibility

;

Development

2010

2015

2018

2019

2020

2021

The First Organoid Construction in China

The founding team successfully constructed intestinal organoids at Tsinghua University.

The First High-level Organoid Paper in China

The founding team applied organoid technology in a paper published in the journal Nature Communications.

Multi-lineage and Multi-cancer Standardized Organoid Technology

Establishing normal and tumor organoid cultures for endodermal organs, achieving industrial translation.

Standardized Reagents and Assay Kits are Now Available

Organregen® GMP-Grade, Stable Strain Growth Factor Pipeline Established, Comprehensively Advancing Organoid Research. bioGenous™ Organoid Multi-Cancer, Whole-Process Kits Now Available

Leading International Organoid Construction for COVID-19 Infection Models

In March 2020, the team successfully constructed the worlds first human-derived organoid model of SARS-CoV-2 infection, which was featured in an interview by Nature and highlighted on its homepage.

Serving Multiple Leading Innovative Pharmaceutical Companies in the Country

Collaborating with leading domestic companies in specialized segments of the innovative drug industry to create successful cases of new drug R&D and non-clinical evaluation systems using organoids.

Model Revolution-Organoid

2009: Hans Clevers' team established the world's first “intestinal organoid”

2013: Science magazine's “Top Ten Breakthroughs of the Year”

2017: Organoids were selected as the Method of the Year by Nature Methods

2018: The first international report on a colorectal cancer organoid drug sensitivity screening system, with a positive predictive accuracy of 88% (Science)

2020: Organoids entered the EU's “Horizon 2020” strategic plan

: Nature reported on how organoids solve the mechanism of SARS-CoV-2 infection

2021: Organoids are included in China's “14th Five-Year” National Key Development Plan

: Organoids, as “astronauts in a petri dish”, have been launched to the Chinese space station

: The CDE-released 'Technical Guidance Principle for Nonclinical Research and Evaluation of Gene-Modified Cell Therapy Products' proposes for the first time that organoid models can be used to assess efficacy and safety

Advantages of Organoid Models

An organoid is a 3D structure formed by culturing adult stem cells or pluripotent stem cells in vitro, which resembles the tissue from which it is derived. Organoids are highly consistent with their source tissues in terms of tissue structure, cell types, self-renewal capacity, and function. As such, they demonstrate unique advantages in various fields of biomedicine, including developmental biology, disease modeling, precision medicine, drug R&D, gene and cell therapies, infection and immunity, and regenerative medicine.

Comparison among Common Research Models

	Cell line	Caenorhabditis elegans	Drosophila melanogaster	Danio rerio	mouse model	PDX model	human-derived organoids
ease of establishment	√ / ×	√	√	√	√	√	√
ease of maintainence	√	√	√	√	√	√	√
developmental simulation	×	√	√	√	√	×	√
experimental cycle	√	√	√	√	√	√	√
gene manipulation	√	√	√	√	√	×	√
genome-wide screening	√	√	√	√	×	×	√
physiological complexity	×	√	√	√	√	√	√
experimental cost	√	√	√	√	√	√	√
simulating the human body	√	√	√	√	√	√	√
best √ good √ partially suitable √ unsuitable ×

About Us